Rep. Doris Matsui (D-CA) today introduced an AHA-supported bill that would make changes to the 340B drug savings program, including overturning last year’s significant Medicare payment reduction for many hospitals in the program and adding program integrity requirements for drug manufacturers participating in the program. “Hospitals and clinics doing life-saving work rely on the 340B program to help them provide inclusive and affordable care in their communities,” Matsui said. “This legislation makes clear the importance of preserving the program so safety net providers can continue to serve low-income and vulnerable patients, while expanding it to help address the opioid crisis.” Specifically, the Stretching Entity Resources for Vulnerable (SERV) Communities Act would overturn the nearly 30% Medicare payment cut that went into effect Jan. 1 for certain hospitals for outpatient drugs purchased under the 340B program. Among other provisions, the bill would require implementation of the long delayed 340B ceiling price calculation methodology and application of civil monetary penalties for manufacturers’ violations of the ceiling price.

Related News Articles

Headline
The United States Court of Appeals for the Fifth Circuit Sept. 12 affirmed a Mississippi Court’s decision to deny AbbVie’s request for a preliminary injunction…
Perspective
Public
Every health care provider strives to deliver their patients the best possible care, but not all providers offer the same level or complexity of care. Current…
Headline
The House Energy and Commerce Subcommittee on Health Sept. 10 advanced the Title VIII Nursing Workforce Reauthorization Act (H.R. 3593), AHA-supported…
Headline
The House Appropriations Committee Sept. 9 advanced the fiscal year 2026 appropriations bill for the Departments of Labor, Health and Human Services, Education…
Headline
A JAMA internal medicine study published Sept. 8 found that since the COVID-19 pandemic, Medicare Advantage beneficiaries have been experiencing longer…
Headline
The AHA Sept. 8 urged the Federal Trade Commission and Antitrust Division of the Department of Justice to investigate several drug companies’ concerted efforts…